Valvular & structural heart disease
Transcatheter Aortic Valve Replacement for Aortic Regurgitation: A Systematic Review and Meta-Analysis
Authors' conclusion
On-label devices showed significantly better safety and efficacy in terms of the success rate, PPI, greater-than-mild PVL, and 30 day mortality than off-label devices.
Study context
- Population
- Patients with severe aortic regurgitation undergoing TAVR with new-generation devices
- Participants
- 1,851 patients31 studies
- Comparison
- On-label vs off-label new-generation TAVR devices
- On-labeln = 1,067
- Outcome
- Device success
- Follow-up
- 30 days
Methodological detailsMEDLINE, Embase, Cochrane Library and Scopus searched through April 2023
- MEDLINE, Embase, Cochrane Library and Scopus searched through April 2023
Pooled result
As reported in the abstract
P < 0.001
- Total device success, all new-generation devices (NGDs)
- 94.5%
Further pooled results
All-cause mortality · 30 days
P = 0.006
- All-cause mortality — All NGDs
- 4.2%
Safety
Permanent pacemaker implantation · 30 days
P < 0.001
Greater-than-mild paravalvular leak · 30 days
P = 0.003
- Permanent pacemaker implantation — All NGDs
- 8.8%
- Greater-than-mild paravalvular leak — All NGDs
- 1.2%
Original publication
Transcatheter Aortic Valve Replacement for Aortic Regurgitation: A Systematic Review and Meta-Analysis. ESC Heart Fail. Published 15 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →